(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of 8.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Editas Medicine's revenue in 2024 is $69,407,000.On average, 9 Wall Street analysts forecast EDIT's revenue for 2024 to be $2,677,339,482, with the lowest EDIT revenue forecast at $90,461,771, and the highest EDIT revenue forecast at $4,827,369,074. On average, 8 Wall Street analysts forecast EDIT's revenue for 2025 to be $2,105,209,896, with the lowest EDIT revenue forecast at $1,422,716,950, and the highest EDIT revenue forecast at $2,604,229,923.
In 2026, EDIT is forecast to generate $9,182,363,225 in revenue, with the lowest revenue forecast at $3,836,401,487 and the highest revenue forecast at $19,904,056,847.